A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
详细描述
This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5 prior lines of therapy
- •Eastern Cooperative Group (ECOG) performance status of 0 or 1
- •Measurable disease by International Working Group (IWG) response criteria for lymphoma
- •Adequate organ and marrow function
排除标准
- •Previous immune-mediated therapy
- •Subjects with prior ASCT or allogenic HCT. Subjects ineligible for available curative options after failing ASCT and have met the hematologic criteria are eligible to participate in this study. Subjects with prior allogenic HCT will be excluded.
- •Documented current central nervous system involvement
- •Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions
- •Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)
研究组 & 干预措施
MEDI4736
干预措施: MEDI4736 (Drug)
MEDI4736 and tremelimumab
干预措施: MEDI4736 (Drug)
MEDI4736 and tremelimumab
干预措施: tremelimumab (Drug)
MEDI4736 and AZD9150
干预措施: MEDI4736 (Drug)
MEDI4736 and AZD9150
干预措施: AZD9150 (Drug)
结局指标
主要结局
Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events
时间窗: Screening through 90 days after the last dose of study medication
Number of subjects experiencing dose-limiting toxicities
时间窗: First dose of study medications through 28 days after the administration of MEDI4736 or MEDI4736 and tremelimumab, 35 days after administration of MEDI4736 and AZD9150
Changes from baseline in laboratory parameters, vital signs, and ECGs
次要结局
- Time to progression(Screening though 3 years after the last subject receives the first dose of study medication)
- Event free survival(Screening though 3 years after the last subject receives the first dose of study medication)
- Number of subjects who develop anti-drug antibodies (ADA)(Screening through 90 days after last dose of study medication)
- Time to Response(Screening though 3 years after the last subject receives the first dose of study medication)
- Duration of Response(Screening though 3 years after the last subject receives the first dose of study medication)
- Overall survival(Screening though 3 years after the last subject receives the first dose of study medication)
- Progression Free survival(Screening though 3 years after the last subject receives the first dose of study medication)
- MEDI4736 Maximum Plasma Concentration (Cmax)(Measured at defined study visits from time of first dose through end of treatment)
- Tremelimumab Maximum Plasma Concentration (Cmax)(Measured at defined study visits from time of first dose through end of treatment)
- AZD9150 Maximum Plasma Concentration (Cmax)(Measured at defined study visits from time of first dose through end of treatment)
- MEDI4736 Minimum Plasma Concentration (Cmin)(Measured at defined study visits from time of first dose through end of treatment)
- Tremelimumab Minimum Plasma Concentration (Cmin)(Measured at defined study visits from time of first dose through end of treatment)
- AZD9150 Minimum Plasma Concentration (Cmin)(Measured at defined study visits from time of first dose through end of treatment)
- Individual MEDI4736 Concentrations(Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months))
- Individual tremelimumab Concentrations(Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months))
- Individual AZD9150 Concentrations(Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months))
- Change from baseline of STAT3 RNA (signal transducer and activator of transcription)(Measured at defined study visits from time of first dose through 90 days after last dose (approximately 15 months))
- Baseline PD-L1 protein expression within the tumor(Measured on tumor samples provided at screening)